Heron Therapeutics
HRTX
3 hedge funds and large institutions have $10.5M invested in Heron Therapeutics in 2013 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, reducing their positions, and closing their positions.
239% more capital invested
Capital invested by funds: $3.1M → $10.5M (+$7.42M)
50% more funds holding
Funds holding: 2 → 3 (+1)
Top Buyers
| 1 |
VM
VHCP Management
New York
|
+$5.78M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$445K |
| 3 |
EEG
E.E. Geduld
|
+$134K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VM
1
VHCP Management
New York
| $9.86M | +$5.78M | +642,350 | +142% |
|
|
2
Alyeska Investment Group
Chicago,
Illinois
| $445K | +$445K | +50,000 | New |
|
|
EEG
3
E.E. Geduld
| $223K | +$134K | +15,000 | +150% |
|
HRTX Hedge Fund Activity: Q4 2013 in Review
3 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q4 2013, worth a combined $10.5M — up 239% from $3.1M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new HRTX positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.
The largest buyer was VHCP Management, adding an estimated $5.78M.
- 3 institutional investors held Heron Therapeutics (HRTX) as of Q4 2013, up from 2 in Q3 2013.
- Funds reported $10.5M of Heron Therapeutics stock for Q4 2013, up 239% quarter-over-quarter.
- 1 fund opened new Heron Therapeutics positions in Q4 2013 and 0 closed out, a net change of +1 holder.
- The largest Heron Therapeutics buyer in Q4 2013 was VHCP Management, an estimated $5.78M added.
Based on aggregated 13F filings for Q4 2013.